phrykt

PMV Pharmaceuticals, Inc. (PMVP): who owns it and who trades it

As of Nov 16, 2026, no open-market insider purchases or sales of PMVP were reported in the last 12 months. 3 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling PMV Pharmaceuticals

From the latest filings

Overall: more buying than selling. Funds mostly sold. Famous investors mostly bought.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns PMVP

63 funds and institutions reported PMVP shares worth $46.4M at the end of Q2 2026, about 65% of the company. The largest holder is BML Capital Management, LLC with 10.0%.

Funds and institutions (13F) 65%Everyone else 35%

10 largest owners, by share of the company

BML Capital Management, LLC10.0%
Tang Capital Management LLC8.0%
Sio Capital Management, LLC4.9%
Euclidean Capital LLC4.9%
Adage Capital Partners Gp, L.l.c.4.4%
Acadian Asset Management LLC4.2%
Vanguard Capital Management LLC3.8%
ArrowMark Colorado Holdings LLC3.7%
Two Sigma Investments, LP3.7%
Eversept Partners, LP3.5%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
BML Capital Management, LLC5.33M9.99%$7.1M+0%
Tang Capital Management LLC4.25M7.96%$5.7MNo change
Sio Capital Management, LLC2.63M4.94%$3.5M-14%
Euclidean Capital LLC2.63M4.93%$3.5MNo change
Adage Capital Partners Gp, L.l.c.2.36M4.43%$3.2M+27%
Acadian Asset Management LLC2.22M4.16%$3MNo change
Vanguard Capital Management LLC2.01M3.77%$2.7M+2%
ArrowMark Colorado Holdings LLC1.96M3.67%$2.6M-32%
Two Sigma Investments, LP1.95M3.66%$2.6M+4%
Eversept Partners, LP1.89M3.55%$2.5M-19%
BlackRock, Inc.919,8181.72%$1.2M+5%
Assenagon Asset Management S.A.660,0061.24%$884K+83%
Stonepine Capital Management, LLC536,0861.01%$718K-24%
Geode Capital Management, LLC473,1580.89%$635K-5%
Aldebaran Capital, LLC467,4320.88%$626K-1%
Bridgeway Capital Management, LLC428,8530.80%$575KNo change
BIT Capital GmbH407,5550.76%$546K+230%
Verdad Advisers, LP362,3610.68%$486K+101%
Walleye Capital LLC335,6940.63%$450KNo change
Marshall Wace, LLP321,6100.60%$431K-26%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

No PMVP insider reported an open-market purchase or sale in the last 12 months.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$0
0 trades, 0 people
Sales under a 10b5-1 plan
–
Share of sale value
Latest trade
–
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

PMVP short interest

Low short interest. 4.0% of PMVP shares are sold short: about 1 share in 25. Over the last 12 reports the number of shares short went down 30%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 2.15M PMVP shares were sold short, 4.0% of the shares outstanding, down 5.8% from the report before. At the average daily volume of 383,345 shares, buying them all back would take about 5.6 trading days (days to cover).

Shares short, % of all shares

4.03%May 15Oct 306.42%

Days to cover

5.6May 15Oct 3012.6

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 20262.15M4.03%-6%383,3455.6
Oct 15, 20262.29M4.27%-18%983,0262.3
Sep 30, 20262.79M5.23%-4%778,1473.6
Sep 15, 20262.92M5.46%+29%1.25M2.3
Aug 31, 20262.27M4.24%+1%268,3078.4
Aug 14, 20262.24M4.20%-6%379,0045.9
Jul 31, 20262.38M4.46%-2%222,83810.7
Jul 15, 20262.42M4.54%-17%386,5066.3
Jun 30, 20262.91M5.46%+1%350,6348.3
Jun 15, 20262.87M5.38%-12%255,08411.2
May 29, 20263.26M6.10%+6%310,56310.5
May 15, 20263.08M5.78%+17%488,3186.3

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

PMV Pharmaceuticals company events

PMV Pharmaceuticals filed 8 reports on Form 8-K in the last 12 months, 1 of them about an important change (leadership). The latest was on Nov 10, 2026.

  1. Nov 10, 2026ResultsReleased financial results. Filing
  2. Oct 5, 2026LeadershipDr. Matthew Eckler was appointed to the board of directors of PMV Pharmaceuticals, Inc. Filing
  3. Sep 2, 2026AgreementPMV Pharmaceuticals, Inc. entered into an underwriting agreement with TD Securities (USA) LLC, relating to an underwritten offering of (i) (a) 22,055,000 shares of the Company’s common stock, $0.00001 par value per share and in lieu of Common Stock to certain investors, (b) pre-funded warrants to… Filing
  4. Aug 31, 2026AnnouncementPMV Pharmaceuticals, Inc. issued a press release announcing updated rezatapopt monotherapy interim ovarian cancer data from the Phase 2 pivotal portion of the PYNNACLE clinical trial. Filing
  5. Aug 14, 2026ResultsReleased financial results. Filing
  6. Jun 5, 2026VoteReported shareholder vote results. Filing
  7. May 12, 2026ResultsReleased financial results. Filing
  8. Mar 6, 2026ResultsReleased financial results. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

PMV Pharmaceuticals financials

Famous investors that hold PMVP

3 of the 50 well-known investors we track reported holding PMVP in their latest 13F filing. The largest position is Israel Englander's, worth $2.4M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Israel Englander · Millennium ManagementQ3 20261.46M$2.4M0.0%New
Ken Griffin · Citadel AdvisorsQ3 2026268,338$448K0.0%+467%
Steve Cohen · Point72 Asset ManagementQ3 202618,819$31.4K0.0%New

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named PMVP in the last 120 days.

FiledHolderFormStake
Nov 16, 2026TANG CAPITAL MANAGEMENT, LLC13G/A10.0%
Nov 16, 2026TANG CAPITAL MANAGEMENT, LLC13G/A10.0%

Questions about PMV Pharmaceuticals, Inc. (PMVP) stock

Who owns the most PMVP stock?

The largest reported owner of PMV Pharmaceuticals, Inc. (PMVP) is BML Capital Management, LLC, with 10.0% of the company. In total, 63 funds and institutions reported holding PMVP at the end of Q2 2026, together about 65% of the shares. See the largest owners.

Are PMVP insiders buying or selling?

No PMVP insider reported an open-market purchase or sale on Form 4 in the last 12 months. Share awards, option exercises and gifts are not counted.

What is the short interest in PMVP?

As of Oct 30, 2026, 2.15M PMVP shares were sold short, 4.0% of the shares outstanding, down 5.8% from the report before. At the average daily volume of 383,345 shares, buying them all back would take about 5.6 trading days (days to cover). See the history.

Which famous investors hold PMVP?

3 of the 50 well-known investors we track reported PMVP in their latest 13F filing, including Israel Englander, Ken Griffin, Steve Cohen. The largest position is worth $2.4M. See all holders.

Executive pay

PMV Pharmaceuticals's chief executive was paid a total of $1.7M for the year ended Dec 31, 2025, down 65% from $4.8M the year before. In the last 12 months, PMV Pharmaceuticals's executives and directors bought no stock on the open market and sold none.

Chief executive, total pay$1.7MYear ended Dec 31, 2025. Salary, bonus and the value of stock and option awards when granted.
Pay "actually paid"$958KThe same year, with stock awards valued at what they were worth as they vested or at year end.
Other top executives, average$898KThe other officers named in the proxy statement.

From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.